PA
OSCR icon

PharVision Advisers’s Oscar Health OSCR Stock Holding History

PharVision Advisers’s Portfolio OSCR Stock Details OSCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-10,998
Closed -$126K – 110
2026
Q1 		$126K Buy
+10,998
New +$155K 1.28% 28
2025
Q4 		– Sell
-11,282
Closed -$214K – 918
2025
Q3 		$214K Buy
+11,282
New +$186K 0.12% 462

Other funds holding OSCR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
TCMNY
Thrive Capital Management (New York) New York $3.81B AUM 45.58% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

PharVision Advisers's OSCR Position: Q2 2026 in Review

PharVision Advisers sold out of Oscar Health (OSCR) in Q2 2026, closing a stake of 10,998 shares — an estimated $126K sold.

PharVision Advisers first reported a position in OSCR in Q3 2025 and held it in 2 quarters. The position peaked at $214K in Q3 2025. 403 funds tracked by Wall St. Rank hold OSCR as of Q2 2026.

  • PharVision Advisers reported no remaining Oscar Health position as of Q2 2026 after selling out during the quarter.
  • PharVision Advisers sold 10,998 Oscar Health shares in Q2 2026, an estimated $126K.
  • PharVision Advisers first reported a position in Oscar Health in Q3 2025 and held it in 2 quarters.
  • PharVision Advisers's Oscar Health position peaked at $214K in Q3 2025.
  • 403 funds tracked by Wall St. Rank held Oscar Health as of Q2 2026.

Based on PharVision Advisers's 13F filing for Q2 2026, filed 11 Aug 2026.